Core Insights - The Shanghai Stock Exchange (SSE) has seen a significant increase in refinancing activities in 2025, with nearly 690 billion yuan raised, supporting the optimization of capital structures and enhancing technological innovation and industrial upgrades [1][2]. Group 1: Refinancing Statistics - As of December 19, 2025, the SSE has accepted 114 companies for refinancing, with 99 registered and 94 issued, raising a total of 687.9 billion yuan [2]. - In the fourth quarter of 2025, the SSE expedited the refinancing review process, with 37 new projects approved and the average review cycle reduced to approximately 2 months [4]. Group 2: Review Process Improvements - The efficiency of the refinancing review process has improved significantly in 2025, particularly after the implementation of the "1+6" policy measures on June 18, which enhanced the review speed for companies on the Sci-Tech Innovation Board [3]. - Companies like Lingrui New Materials and Microchip Biotech have experienced review times of less than 70 days for their refinancing projects, indicating a notable acceleration in the process [3]. Group 3: Simplified Procedures - The simplified refinancing procedure has emerged as a "fast track," allowing companies to quickly raise funds without extensive exchange reviews, significantly enhancing financing efficiency [5]. - For instance, Zhimin Technology successfully raised 208 million yuan through this simplified procedure for research and development in unmanned equipment and commercial aerospace [5]. Group 4: Support for High-Tech Companies - The "light asset, high R&D investment" standard has been instrumental in supporting the growth of high-tech companies, allowing them to bypass certain restrictions and increase their financing capabilities [8]. - Since the introduction of this standard in October 2024, 14 companies on the Sci-Tech Innovation Board have utilized it, collectively seeking 35.12 billion yuan, which represents 38% of the companies and 76% of the financing amounts in 2025 [8][9]. Group 5: Diverse Company Profiles - Companies adopting the "light asset, high R&D investment" standard span all five listing criteria of the Sci-Tech Innovation Board, showcasing the board's inclusive nature [9]. - Notable companies include Lexin Technology and Cambricon, which have successfully completed their financing under this standard, highlighting its effectiveness in facilitating capital access for innovative firms [9].

Core Insights - The refinancing scale in the Shanghai Stock Exchange (SSE) for 2025 has reached nearly 690 billion yuan, significantly supporting the optimization of capital structures and enhancing technological innovation and industrial upgrades for listed companies [1][2]. Group 1: Refinancing Efficiency - The efficiency of refinancing reviews in the SSE has improved significantly in 2025, with a notable acceleration in the review process following the implementation of the "1+6" policy measures on June 18 [3]. - As of December 19, 2025, the average review cycle for refinancing projects has been compressed to around 2 months, with some projects, such as those from Xianghe Industrial and Haitian Flavoring, being approved in as little as 40 days [3]. - The SSE has enhanced communication and consultation efficiency, further shortening the review cycle by actively reminding and responding to major issues during the review process [3]. Group 2: Simplified Procedures - The simplified refinancing procedure has emerged as a "fast track" for refinancing, allowing companies to autonomously decide on fundraising purposes without needing exchange review, thus significantly improving financing efficiency [4]. - Recently, Zhimin Technology successfully raised 208 million yuan through the simplified procedure for research and industrialization projects in the fields of unmanned equipment and commercial aerospace [4]. - The simplified procedure has enabled companies to complete financing within the year, addressing urgent funding needs and enhancing certainty in financing [4]. Group 3: Light Asset and High R&D Standards - The "light asset, high R&D input" standard has empowered high-tech companies to meet their funding needs for research and development, with 14 companies in the SSE adopting this standard since its introduction in October 2024 [6]. - These companies have collectively planned to raise 35.12 billion yuan, representing 38% of the number of companies and 76% of the total financing amount in the SSE for 2025 [6]. - The standard has effectively supported the financing development of high-growth "hard tech" enterprises, with companies like Cambricon and Dizhe Pharmaceutical successfully raising funds under this standard [7]. Group 4: Diverse Listing Standards - Companies utilizing the "light asset, high R&D input" standard have demonstrated the diverse and inclusive characteristics of the SSE, with applicants spanning all five listing standards [8]. - Notable companies include Lexin Technology and Zhongke Xingtu, which have successfully registered under various listing standards, showcasing the adaptability of the SSE to different business models [8].

Core Viewpoint - The "light asset, high R&D investment" standard has become the main method for refinancing on the Sci-Tech Innovation Board, with 14 companies adopting this standard to apply for refinancing, aiming to raise a total of 35.12 billion yuan, accounting for 38% and 76% of the companies accepted for refinancing in 2025 respectively [1][7]. Group 1: Refinancing Standards and Impact - The Shanghai Stock Exchange supports the financing development of high-growth "hard tech" companies, helping them overcome development bottlenecks [1]. - The "light asset, high R&D investment" standard allows companies to exceed the 30% limit on supplementary liquidity, increasing R&D innovation efforts [7]. - The first project using the simplified procedure under this standard was completed by Chengdu Zhimingda Electronics Co., Ltd., raising 208 million yuan for R&D and working capital [7][8]. Group 2: Efficiency of Review Process - Since the implementation of the pilot registration system, 24 companies have quickly obtained registration approval through simplified procedures, significantly enhancing market perception [2]. - The review efficiency has improved, with projects like China Software and Technology Service Co., Ltd. and Cambrian Technology obtaining registration within three months [3]. - The review process has been streamlined, allowing companies to complete payments within ten working days after obtaining approval from the CSRC [2][3]. Group 3: Case Studies and Company Insights - Micron Biotech's rapid approval of its financing project is crucial for accelerating R&D and industrialization, enhancing its strategic development certainty [4]. - Cambrian Technology raised 3.985 billion yuan for projects related to AI chips, with a registration period of 92 days [4]. - Lianrui New Materials' convertible bond project was approved in 65 days, aiming to raise 695 million yuan for high-performance materials [4]. Group 4: Market Trends and Future Outlook - The focus of refinancing projects is on strategic emerging industries, including integrated circuit IP design and semiconductor equipment manufacturing, reflecting the capital market's support for technological innovation [6][9]. - The continuous optimization of the refinancing system on the Sci-Tech Innovation Board is expected to lead to breakthroughs in key core technologies by more tech companies [9].

Core Insights - The refinancing scale in the Shanghai Stock Exchange (SSE) has reached nearly 690 billion yuan in 2025, significantly supporting the optimization of capital structures and enhancing technological innovation and industrial upgrades for listed companies [1] Group 1: Refinancing Efficiency - The efficiency of refinancing review in the SSE has improved significantly in 2025, with a notable acceleration following the implementation of the "1+6" policy measures for the Sci-Tech Innovation Board on June 18 [2] - As of December 19, 2025, the review cycle for refinancing projects has been compressed to around 2 months, with some projects approved in as little as 40 days [3] Group 2: Simplified Procedures - The simplified procedure for refinancing has proven effective, allowing companies to quickly raise funds without extensive review processes, thus enhancing financing efficiency [4] - Companies like Zhimingda have successfully utilized the simplified procedure to raise 208 million yuan for research and development projects, addressing urgent financing needs [4] Group 3: Support for High-Tech Enterprises - The "light asset, high R&D investment" standard has been adopted by 14 companies on the Sci-Tech Innovation Board, allowing them to raise a total of 35.12 billion yuan, thus facilitating innovation and growth [6][7] - This standard has become a primary choice for high-growth "hard tech" companies, with significant participation from sectors such as new-generation information technology and biomedicine [7][8]

Core Insights - The refinancing review process has been significantly expedited, with an average approval cycle of around 2 months, marking a reduction from previous timelines [1][2][3] - The "light asset, high R&D investment" standard has become a primary choice for companies on the Sci-Tech Innovation Board for refinancing, with 14 companies adopting this standard since its introduction in October 2024, aiming to raise a total of 35.12 billion yuan [1][6] Group 1: Refinancing Review Process - A total of 37 refinancing projects were approved in the Shanghai market from the fourth quarter of 2025 to December 19, with the fastest project taking only 40 days for approval [1][3] - The simplified refinancing procedure allows companies to autonomously decide on fundraising uses, enhancing efficiency by eliminating the need for exchange review inquiries [2][3] - The implementation of the simplified procedure has been extended from the Sci-Tech Innovation Board to the main board, further facilitating refinancing processes [2] Group 2: Adoption of New Standards - The "light asset, high R&D investment" standard has been adopted by 14 companies, with the total proposed financing amounting to 35.12 billion yuan, representing 38% of the number of companies and 76% of the financing amount in 2025 [1][6] - Companies like Zhimin Da have successfully issued new shares under this standard, significantly shortening the review time and addressing urgent financing needs [1][6][8] - The standard has allowed companies to exceed the previous 30% limit on liquidity ratios, thereby increasing R&D investment and innovation capabilities [6] Group 3: Impact on Companies - Companies such as Microchip Biotech and Lianrui New Materials have reported that rapid approval of their refinancing projects will enhance their funding sources and accelerate innovation in drug development [4][3] - The successful adoption of the "light asset, high R&D investment" standard has enabled companies to align their fundraising efforts with national economic development strategies [6][7] - The focus on real business and funding needs has been emphasized by companies to ensure the success of their refinancing applications [8]

北京商报讯（记者 王寅浩 宋雨盈）12月18日，迪哲医药发布公告称，因个人工作原因，王学恭申请辞 去公司独立董事、董事会审计委员会委员、薪酬与考核委员会委员、提名委员会主任委员以及战略委员 会委员职务，辞去上述职务后，王学恭不再担任公司任何职务。公司将按照相关规定，尽快完成新任独 立董事的补选工作。 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-65 为保障公司董事会的规范运作，王学恭先生在独立董事改选期间将继续履 行职责，其辞职报告将在公司股东会选举产生新任独立董事后生效。公司将按 照相关规定，尽快完成新任独立董事的补选工作。独立董事改选不会影响董事 会正常运行，不会对本公司日常管理及生产经营产生不利影响。截至本公告披 露日，王学恭先生未持有公司股份。 王学恭先生在担任公司独立董事、董事会审计委员会委员、薪酬与考核委 员会委员、提名委员会主任委员以及战略委员会委员期间恪尽职守、勤勉尽责， 为公司的规范治理和良好发展发挥了重要作用。在此，公司董事会对其在担任 董事及委员职务期间为公司发展所作出的贡献表示衷心的感谢！ 特此公告。 迪哲（江苏）医药股份有限公司董事会 2025 年 12 月 19 日 1 迪哲（江苏）医药股份有限公司 关于公司独立董事辞职的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"）董事会于近日收到 公司独立董事王学恭先生的辞职报告。 ...

格隆汇12月18日丨迪哲医药(688192.SH)公布，公司董事会于近日收到公司独立董事王学恭先生的辞职 报告。因个人工作原因，王学恭先生申请辞去公司独立董事、董事会审计委员会委员、薪酬与考核委员 会委员、提名委员会主任委员以及战略委员会委员职务。辞去上述职务后，王学恭先生不再担任公司任 何职务。 ...

格隆汇12月18日丨迪哲医药(688192.SH)公布，公司董事会于近日收到公司独立董事王学恭先生的辞职 报告。因个人工作原因，王学恭先生申请辞去公司独立董事、董事会审计委员会委员、薪酬与考核委员 会委员、提名委员会主任委员以及战略委员会委员职务。辞去上述职务后，王学恭先生不再担任公司任 何职务。 ...

证券日报网讯 12月17日晚间，迪哲医药发布公告称，公司第二届董事会第十七次会议审议通过《关于 2022年限制性股票激励计划首次授予及预留授予部分限制性股票符合归属条件的议案》《关于变更注册 资本、修订公司章程并办理工商变更登记的议案》等多项议案。 （文章来源：证券日报） ...